Q-omics provides the consensus-scored FTX profile across patient tissues and cancer cell-line models. FTX expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FTX is differentially expressed in 11, with the highest sampling consensus in UCEC. Additionally, FTX RNA expression shows 21,309 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, and UVM as cancer lineages where FTX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTX survival associations across molecular data types. FTX RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTX RNA expression–survival associations across cancer types. High FTX expression shows unfavorable associations in UCEC, LUSC, UVM and BRCA, but favorable associations in UCS and ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify UCEC as the clearest survival context for FTX RNA expression.
This table summarizes FTX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FTX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTX shows lower tumor expression in UCEC, LUSC, KICH and BRCA and higher tumor expression in COAD and HNSC. The UCEC box plot shows higher FTX RNA expression in normal versus tumor tissue (log2 FC = −0.643, t-test p < 0.001).
This table shows molecular features associated with FTX in patient tissues and cancer cell lines. In patient samples, FTX shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
